Navigation Links
BHR Pharma Expands SyNAPSe® Trial into Thailand, China and Russia
Date:6/12/2012

HERNDON, Va., June 12, 2012 /PRNewswire/ -- BHR Pharma's SyNAPSe® clinical trial is now enrolling patients suffering from severe traumatic brain injury (TBI) at 14 sites in Thailand, China and Russia.  The trial currently has 153 participating sites (Level 1 and 2 trauma centers) worldwide.

The 500th of 1,180 patients needed to complete the global Phase III, multi-center trial was enrolled at the end of May in the United States.

SyNAPSe is evaluating the effectiveness of BHR-100, a proprietary intravenous progesterone infusion formulation, as a neuroprotective agent for treating severe TBI patients. The U.S. Food and Drug Administration had granted Orphan Drug designation to BHR-100 and have placed the drug on a Fast Track status designed to accelerate its potential approval.

"In the past four months we've added 28 clinical trial sites, including additional centers in the United States and Europe, and we're working towards opening six Malaysian sites in the near future," said Thomas W. MacAllister, JD, PhD, President & CEO of BHR Pharma.  "We're on track to complete enrollment for this pivotal clinical trial early next year, with the intent of bringing the first-ever treatment for TBI to market."

TBI is a serious public health problem that affects more than 1.7 million Americans each year. Despite significant efforts in more than 75 clinical trials over the past 20 years, there is still no approved treatment for TBI.

Previous research has shown progesterone exerts its neuroprotective effects by protecting or rebuilding the blood-brain barrier, decreasing development of cerebral edema (brain swelling), down-regulating the inflammatory cascade and limiting cellular necrosis and apoptosis (programmed cell death). 

"Unfortunately, little can be done to reverse the initial brain damage caused by a TBI. Once a TBI occurs, medical treatment focuses on p
'/>"/>

SOURCE BHR Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New company announcement: TERGUS PHARMA
2. Berg Pharma presents at ASCO, poised to lead field in cancer metabolism with Phase II trials of BPM 31510
3. Terry Yon Encourages Higher Standards of Pharmaceutical Care
4. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
5. Community Pharmacists Take on Medication Non-Adherence to Improve Patient Health
6. Argus Expands Specialty Pharmacy with Amber Pharmacy Collaboration
7. PharmaNet/i3 Receives Distinguished Partner Award from the US Chinese Anti-Cancer Association
8. Valeant Pharmaceuticals To Host Investor Day
9. OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers
10. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
11. InnoPharma Inc. Raises $8 Million in Venture Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014  Talyst, a market ... 2014 LeadingAge Annual Meeting in Nashville, TN. ... System, the market leading solution for onsite, remote medication ... term care facilities to safely and securely dispense medication ... to first dose, helps ensure that the correct medication ...
(Date:10/17/2014)... , Oct. 17, 2014  Ameritox SM , ... the appointment of Thomas Smith , M.D., as ... a field-based team offering scientific resources for healthcare providers, ... has held leadership positions at a variety of healthcare ... benefit both the pain and behavioral health sides of ...
(Date:10/17/2014)... 2014   DaVita HealthCare Partners Inc. ... nation,s largest and most innovative health care communities, ... the company,s award-winning, leadership development and cultural orientation ... from around the globe were in attendance for ... is a two-day one-of-a-kind experience for new and ...
Breaking Medicine Technology:Talyst Exhibits at LeadingAge Annual Meeting 2Ameritox Appoints New Chief Medical Officer 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3
... Naurex Inc., a clinical-stage company developing innovative ... today announced that it has initiated a Phase II ... Glycine-site Functional Partial Agonist (GFPA) selective modulator of the ... therapy for patients who are not achieving an adequate ...
... 2011 Cempra Pharmaceuticals Inc. today announced that ... present at the 2011 Wells Fargo Healthcare Conference at ... Fernandes will provide an overview of the company,s two ... and other infections and TAKSTA™ for the oral treatment ...
Cached Medicine Technology:Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 3
(Date:10/20/2014)... 2014 Final Cut Pro X Plugin developers ... Citrus theme for FCPX filmmakers . , “Fun, cool, ... the Citrus theme” Says Christina Austin, CEO of Pixel Film ... professional.” , Citrus comes with all the tools needed for ... four transitions for added style, a title screen for an ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... his innovative True Form Tummy Tuck® method ... faculty at The University of Texas Medical Branch ... a medical student. Patronella, who is a founding partner ... practices in Texas, The Aesthetic Center for Plastic ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law ... greater Phoenix area and across Arizona reports record demand ... automobile accidents. Statistics have indicated a steady increase in ... such, Hastings and Hastings has seen a steady increase ... have been injured through no fault of their own ...
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular suppliers ... bamboo deckings . Moreover, the company has launched ... now available at deeply discounted rates. , As ... overstate the significance of online business nowadays. Thus, BambooIndustry.com ... company’s workers are striving to deliver both value and ...
Breaking Medicine News(10 mins):Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
... gave physicians seemingly miraculous weapons against infectious disease. ... and tuberculosis were suddenly at hand. Moreover, many ... versatile enough to knock out a wide range ... a fundamental limitation: They,re useless against viruses, which ...
... team from the National Taiwan University Hospital has evaluated ... models severely damaged by two kinds of chemical toxicity ... to efficiently repopulate the toxin-induced, severely damaged livers. The ... double issue of Cell Transplantation (18:10/11) and ...
... Surgeons who engage in minimally invasive, laparoscopic surgery are ... their own detriment. That,s the finding of the largest ... perform laparoscopic procedures. The survey, developed at the University ... 87 percent of laparoscopic surgeons have experienced physical symptoms ...
... ... Integration and Strong Business Intelligence Allows for Real-Time Monitoring and Better Decision Making ... ... integration and interoperability solutions, announced today it has entered a strategic partnership agreement ...
... ... of managed network services to help regional SMBs build a solid IT foundation to ... ... provider of managed IT services for Texas-based small- and medium-sized businesses, today ...
... , , , , BEIJING , ... or the "Company"), a leading China -based vaccine manufacturer,announced today ... exercised in full their option to purchase an,additional 1,500,000 common shares ... and sell a total of 11,500,000 common shares,at $5.75 ...
Cached Medicine News:Health News:Compound found that targets wide range of viruses 2Health News:Beyond liver transplants: Acutely damaged livers may be repaired via transplanted hepatocytes 2Health News:Survey finds many surgeons suffer injuries from minimally invasive techniques 2Health News:Survey finds many surgeons suffer injuries from minimally invasive techniques 3Health News:Survey finds many surgeons suffer injuries from minimally invasive techniques 4Health News:BridgeGate and Information Builders form Strategic Partnership to Extend Integration Capability for Healthcare and Government Markets 2Health News:BridgeGate and Information Builders form Strategic Partnership to Extend Integration Capability for Healthcare and Government Markets 3Health News:Pivot Networks and Brookside Technology Partners, Inc. Team to Broaden Managed IT Services Offering for Texas SMBs 2Health News:Pivot Networks and Brookside Technology Partners, Inc. Team to Broaden Managed IT Services Offering for Texas SMBs 3Health News:Sinovac Announces Exercise of Over-Allotment Option 2Health News:Sinovac Announces Exercise of Over-Allotment Option 3
Gentamicin is an aminoglycosidic antibiotic that inhibits bacterial growth by inhibiting protein synthesis. Gentamicin is used for prevention and elimination of bacterial contaminants in cell culture...
LB Agar plates with 10mM Magnesium Sulfate....
LB Agar plates with 0.1mM EDTA....
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
Medicine Products: